PA8635201A1 - Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos - Google Patents

Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos

Info

Publication number
PA8635201A1
PA8635201A1 PA20058635201A PA8635201A PA8635201A1 PA 8635201 A1 PA8635201 A1 PA 8635201A1 PA 20058635201 A PA20058635201 A PA 20058635201A PA 8635201 A PA8635201 A PA 8635201A PA 8635201 A1 PA8635201 A1 PA 8635201A1
Authority
PA
Panama
Prior art keywords
same
treatment
micobacterial
diseases
drug resistant
Prior art date
Application number
PA20058635201A
Other languages
English (en)
Spanish (es)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Gestel Jozef Frans Elisabeth Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8635201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8635201A1 publication Critical patent/PA8635201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PA20058635201A 2004-05-28 2005-05-27 Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos PA8635201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04102402 2004-05-28

Publications (1)

Publication Number Publication Date
PA8635201A1 true PA8635201A1 (es) 2006-05-16

Family

ID=34929150

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058635201A PA8635201A1 (es) 2004-05-28 2005-05-27 Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos

Country Status (34)

Country Link
US (2) US20070249667A1 (cg-RX-API-DMAC7.html)
EP (1) EP1753427B1 (cg-RX-API-DMAC7.html)
JP (2) JP5081617B2 (cg-RX-API-DMAC7.html)
KR (2) KR101371653B1 (cg-RX-API-DMAC7.html)
CN (2) CN102908347A (cg-RX-API-DMAC7.html)
AP (1) AP2037A (cg-RX-API-DMAC7.html)
AR (1) AR049127A1 (cg-RX-API-DMAC7.html)
AT (1) ATE390925T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005249231B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510414B1 (cg-RX-API-DMAC7.html)
CA (1) CA2566544C (cg-RX-API-DMAC7.html)
CL (1) CL2009001980A1 (cg-RX-API-DMAC7.html)
CY (1) CY1110388T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005005810T2 (cg-RX-API-DMAC7.html)
DK (1) DK1753427T3 (cg-RX-API-DMAC7.html)
EA (1) EA010651B1 (cg-RX-API-DMAC7.html)
ES (1) ES2306146T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20080307T3 (cg-RX-API-DMAC7.html)
IL (1) IL179630A (cg-RX-API-DMAC7.html)
JO (1) JO2524B1 (cg-RX-API-DMAC7.html)
ME (1) ME01105B (cg-RX-API-DMAC7.html)
MX (1) MXPA06013888A (cg-RX-API-DMAC7.html)
MY (1) MY140611A (cg-RX-API-DMAC7.html)
NO (1) NO338624B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ550840A (cg-RX-API-DMAC7.html)
PA (1) PA8635201A1 (cg-RX-API-DMAC7.html)
PL (1) PL1753427T3 (cg-RX-API-DMAC7.html)
PT (1) PT1753427E (cg-RX-API-DMAC7.html)
RS (1) RS50585B (cg-RX-API-DMAC7.html)
SI (1) SI1753427T1 (cg-RX-API-DMAC7.html)
TW (1) TWI363625B (cg-RX-API-DMAC7.html)
UA (1) UA90267C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005117875A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200609899B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249231B2 (en) * 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
EA009779B1 (ru) * 2004-12-24 2008-04-28 Янссен Фармацевтика Н.В. Лечение латентного туберкулёза
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
HRP20170044T1 (hr) * 2005-06-28 2017-03-10 Janssen Pharmaceutica Nv Derivati kinolina kao antibakterijska sredstva
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2685B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
CA2772786A1 (en) * 2009-09-11 2011-03-17 Vertex Pharmaceuticals Incorporated Compositions of n-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]-n-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]propanamide and uses thereof
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
MX358506B (es) 2012-04-27 2018-08-22 Janssen Pharmaceutica Nv Derivados de quinolina antibacterianos.
EP2841425B1 (en) 2012-04-27 2016-03-23 Janssen Pharmaceutica, N.V. Antibacterial quinoline derivatives
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
EP3170810B1 (en) * 2014-07-14 2018-09-19 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
UA126891C2 (uk) 2015-01-27 2023-02-22 Янссен Фармацевтика Нв Здатні до диспергування композиції
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
RU2018111482A (ru) * 2015-10-20 2019-11-21 Чжэцзян Хисунь Фармасьютикал Ко., Лтд. Кристаллические формы бедаквилин фумарата и способы их получения
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
ES2934785T3 (es) * 2016-03-07 2023-02-27 Global Alliance For Tb Drug Development Inc Compuestos antibacterianos y usos de los mismos
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN111278985B (zh) * 2017-09-01 2023-09-08 学校法人北里研究所 具有针对鸟分枝杆菌复合体感染疾病治疗活性的新型化合物及其制造方法
WO2020047596A1 (en) * 2018-09-04 2020-03-12 Monash University Antibacterial compounds and methods of use
WO2020144197A1 (en) 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases
US20230348436A1 (en) * 2019-11-26 2023-11-02 Nanyang Technological University Compounds for treating tuberculosis
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
EP4243800A1 (en) 2020-11-12 2023-09-20 JANSSEN Pharmaceutica NV Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
CN117050006A (zh) * 2022-05-13 2023-11-14 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023227123A1 (zh) * 2022-05-27 2023-11-30 广州嘉越医药科技有限公司 吡啶衍生物的用途
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
WO2024107555A1 (en) * 2022-11-15 2024-05-23 Eli Lilly And Company Ahr agonists
WO2025068448A1 (en) 2023-09-28 2025-04-03 Janssen Pharmaceutica Nv Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399558A (en) * 1993-11-24 1995-03-21 Pathogenesis Corporation Isoflavonoid antibacterial compounds, compositions and use
CA2270123A1 (en) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
JP4484703B2 (ja) * 2002-07-25 2010-06-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用
AU2005249231B2 (en) * 2004-05-28 2010-11-11 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Also Published As

Publication number Publication date
JP5081617B2 (ja) 2012-11-28
CY1110388T1 (el) 2015-04-29
KR101371653B1 (ko) 2014-03-07
PT1753427E (pt) 2008-07-04
DK1753427T3 (da) 2008-07-21
AP2037A (en) 2009-10-09
UA90267C2 (ru) 2010-04-26
MXPA06013888A (es) 2007-01-26
HK1106136A1 (en) 2008-03-07
HRP20080307T3 (hr) 2008-07-31
AU2005249231A1 (en) 2005-12-15
PL1753427T3 (pl) 2008-09-30
CN1976704A (zh) 2007-06-06
BRPI0510414A (pt) 2007-10-23
DE602005005810D1 (de) 2008-05-15
NO20066041L (no) 2007-02-27
IL179630A (en) 2011-05-31
CN1976704B (zh) 2012-12-05
EA200602260A1 (ru) 2007-04-27
ME01105B (me) 2013-03-20
KR20130024969A (ko) 2013-03-08
JO2524B1 (en) 2010-03-17
BRPI0510414B1 (pt) 2022-04-05
TW200608974A (en) 2006-03-16
CN102908347A (zh) 2013-02-06
JP2008500992A (ja) 2008-01-17
CA2566544C (en) 2012-04-17
TWI363625B (en) 2012-05-11
EP1753427A1 (en) 2007-02-21
KR20070017393A (ko) 2007-02-09
NZ550840A (en) 2010-01-29
DE602005005810T2 (de) 2009-04-09
US20070249667A1 (en) 2007-10-25
EP1753427B1 (en) 2008-04-02
EA010651B1 (ru) 2008-10-30
ES2306146T3 (es) 2008-11-01
AU2005249231B2 (en) 2010-11-11
WO2005117875A1 (en) 2005-12-15
SI1753427T1 (sl) 2008-10-31
JP2012229239A (ja) 2012-11-22
ZA200609899B (en) 2009-01-28
US20100168133A1 (en) 2010-07-01
NO338624B1 (no) 2016-09-19
AP2006003828A0 (en) 2006-12-31
JP5675718B2 (ja) 2015-02-25
MY140611A (en) 2009-12-31
CL2009001980A1 (es) 2010-04-16
AR049127A1 (es) 2006-06-28
CA2566544A1 (en) 2005-12-15
ATE390925T1 (de) 2008-04-15
RS50585B (sr) 2010-05-07
IL179630A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
PA8635201A1 (es) Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos
MX2021010674A (es) Compuestos triciclicos condensados utiles como agentes anticancerigenos.
MX2019010736A (es) Inhibidor del antigeno de superficie del virus de la hepatitis b.
MX343215B (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos.
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
UY31676A1 (es) "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
CY1119252T1 (el) Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
MX2020005735A (es) Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
PE20151607A1 (es) Formulaciones de compuestos organicos
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.